0	3	The	the	DT
4	8	AP-1	ap-1	NN
9	13	site	site	NN
14	16	at	at	IN
17	21	-150	-150	CD
22	24	bp	bp	NN
24	25	,	,	,
26	29	but	but	CC
30	33	not	not	RB
34	37	the	the	DT
38	46	NF-kappa	NF-kappa	NNP
47	48	B	B	NNP
49	53	site	site	NN
53	54	,	,	,
55	57	is	be	VBZ
58	64	likely	likely	JJ
65	67	to	to	TO
68	77	represent	represent	VB
78	81	the	the	DT
82	87	major	major	JJ
88	94	target	target	NN
95	97	of	of	IN
98	105	protein	protein	NN
106	112	kinase	kinase	NNP
113	114	C	C	NNP
115	117	in	in	IN
118	121	the	the	DT
122	133	interleukin	interleukin	NN
134	135	2	2	CD
136	144	promoter	promoter	NN
144	145	.	.	.

147	158	Stimulation	stimulation	NN
159	161	of	of	IN
162	163	T	t	NN
164	169	cells	cell	NNS
170	174	with	with	IN
175	182	antigen	antigen	NN
183	190	results	result	VBZ
191	193	in	in	IN
194	204	activation	activation	NN
205	207	of	of	IN
208	215	several	several	JJ
216	223	kinases	kinase	NNS
223	224	,	,	,
225	234	including	include	VBG
235	242	protein	protein	NN
243	249	kinase	kinase	NNP
250	251	C	C	NNP
252	253	(	(	(
253	256	PKC	PKC	NNP
256	257	)	)	)
257	258	,	,	,
259	263	that	that	WDT
264	267	may	may	MD
268	275	mediate	mediate	VB
276	279	the	the	DT
280	285	later	later	JJ
286	295	induction	induction	NN
296	298	of	of	IN
299	317	activation-related	activation-related	JJ
318	323	genes	gene	NNS
323	324	.	.	.

325	327	We	we	PRP
328	332	have	have	VBP
333	341	examined	examine	VBN
342	345	the	the	DT
346	355	potential	potential	JJ
356	360	role	role	NN
361	363	of	of	IN
364	367	PKC	PKC	NNP
368	370	in	in	IN
371	380	induction	induction	NN
381	383	of	of	IN
384	387	the	the	DT
388	399	interleukin	interleukin	NN
400	401	2	2	CD
402	403	(	(	(
403	407	IL-2	il-2	NN
407	408	)	)	)
409	413	gene	gene	NN
414	416	in	in	IN
417	418	T	t	NN
419	424	cells	cell	NNS
425	435	stimulated	stimulate	VBN
436	443	through	through	IN
444	447	the	the	DT
448	449	T	t	NN
450	454	cell	cell	NN
455	467	receptor/CD3	receptor/cd3	NN
468	475	complex	complex	NN
475	476	.	.	.

477	479	We	we	PRP
480	484	have	have	VBP
485	495	previously	previously	RB
496	501	shown	show	VBN
502	506	that	that	IN
507	516	prolonged	prolonged	JJ
517	526	treatment	treatment	NN
527	529	of	of	IN
530	533	the	the	DT
534	547	untransformed	untransformed	JJ
548	549	T	t	NN
550	554	cell	cell	NN
555	560	clone	clone	NN
561	565	Ar-5	ar-5	NN
566	570	with	with	IN
571	578	phorbol	phorbol	NN
579	585	esters	ester	NNS
586	593	results	result	VBZ
594	596	in	in	IN
597	611	downmodulation	downmodulation	NN
612	614	of	of	IN
615	618	the	the	DT
619	624	alpha	alpha	NN
625	628	and	and	CC
629	633	beta	beta	NN
634	642	isozymes	isozyme	NNS
643	645	of	of	IN
646	649	PKC	PKC	NNP
649	650	,	,	,
651	654	and	and	CC
655	664	abrogates	abrogate	VBZ
665	674	induction	induction	NN
675	677	of	of	IN
678	682	IL-2	il-2	NN
683	687	mRNA	mRNA	NNP
688	691	and	and	CC
692	699	protein	protein	NN
699	700	.	.	.

701	705	Here	here	RB
706	708	we	we	PRP
709	713	show	show	VBP
714	718	that	that	IN
719	726	phorbol	phorbol	NN
727	732	ester	ester	NN
733	742	treatment	treatment	NN
743	747	also	also	RB
748	757	abolishes	abolish	VBZ
758	767	induction	induction	NN
768	770	of	of	IN
771	786	chloramphenicol	chloramphenicol	NN
787	804	acetyltransferase	acetyltransferase	NN
805	813	activity	activity	NN
814	816	in	in	IN
817	821	Ar-5	ar-5	NN
822	827	cells	cell	NNS
828	839	transfected	transfecte	VBN
840	844	with	with	IN
845	846	a	a	DT
847	854	plasmid	plasmid	NN
855	865	containing	contain	VBG
866	869	the	the	DT
870	874	IL-2	il-2	NN
875	883	promoter	promoter	NN
884	890	linked	link	VBN
891	893	to	to	TO
894	898	this	this	DT
899	907	reporter	reporter	NN
908	912	gene	gene	NN
912	913	.	.	.

914	917	The	the	DT
918	922	IL-2	il-2	NN
923	931	promoter	promoter	NN
932	940	contains	contain	VBZ
941	948	binding	bind	VBG
949	954	sites	site	NNS
955	958	for	for	IN
959	966	nuclear	nuclear	JJ
967	974	factors	factor	NNS
975	984	including	include	VBG
985	991	NFAT-1	nfat-1	NN
991	992	,	,	,
993	996	Oct	Oct	NNP
996	997	,	,	,
998	1006	NF-kappa	NF-kappa	NNP
1007	1008	B	B	NNP
1008	1009	,	,	,
1010	1013	and	and	CC
1014	1018	AP-1	ap-1	NN
1018	1019	,	,	,
1020	1025	which	which	WDT
1026	1029	are	be	VBP
1030	1033	all	all	RB
1034	1045	potentially	potentially	RB
1046	1055	sensitive	sensitive	JJ
1056	1058	to	to	TO
1059	1069	activation	activation	NN
1070	1072	of	of	IN
1073	1076	PKC	PKC	NNP
1076	1077	.	.	.

1078	1080	We	we	PRP
1081	1085	show	show	VBP
1086	1090	that	that	IN
1091	1100	induction	induction	NN
1101	1103	of	of	IN
1104	1105	a	a	DT
1106	1112	trimer	trimer	NN
1113	1115	of	of	IN
1116	1119	the	the	DT
1120	1124	NFAT	NFAT	NNP
1125	1128	and	and	CC
1129	1132	Oct	Oct	NNP
1133	1138	sites	site	NNS
1139	1141	is	be	VBZ
1142	1145	not	not	RB
1146	1155	sensitive	sensitive	JJ
1156	1158	to	to	TO
1159	1166	phorbol	phorbol	NN
1167	1172	ester	ester	NN
1173	1182	treatment	treatment	NN
1182	1183	,	,	,
1184	1187	and	and	CC
1188	1192	that	that	IN
1193	1202	mutations	mutation	NNS
1203	1205	in	in	IN
1206	1209	the	the	DT
1210	1218	NF-kappa	NF-kappa	NNP
1219	1220	B	B	NNP
1221	1225	site	site	NN
1226	1230	have	have	VBP
1231	1233	no	no	DT
1234	1240	effect	effect	NN
1241	1243	on	on	IN
1244	1256	inducibility	inducibility	NN
1257	1259	of	of	IN
1260	1263	the	the	DT
1264	1268	IL-2	il-2	NN
1269	1277	promoter	promoter	NN
1277	1278	.	.	.

1279	1281	In	in	IN
1282	1290	contrast	contrast	NN
1290	1291	,	,	,
1292	1301	mutations	mutation	NNS
1302	1304	in	in	IN
1305	1308	the	the	DT
1309	1313	AP-1	ap-1	NN
1314	1318	site	site	NN
1319	1326	located	located	JJ
1327	1329	at	at	IN
1330	1334	-150	-150	CD
1335	1337	bp	bp	NN
1338	1344	almost	almost	RB
1345	1355	completely	completely	RB
1356	1364	abrogate	abrogate	VBP
1365	1374	induction	induction	NN
1375	1377	of	of	IN
1378	1381	the	the	DT
1382	1386	IL-2	il-2	NN
1387	1395	promoter	promoter	NN
1395	1396	,	,	,
1397	1400	and	and	CC
1401	1411	appearance	appearance	NN
1412	1414	of	of	IN
1415	1417	an	an	DT
1418	1427	inducible	inducible	JJ
1428	1435	nuclear	nuclear	JJ
1436	1442	factor	factor	NN
1443	1450	binding	bind	VBG
1451	1453	to	to	TO
1454	1458	this	this	DT
1459	1463	site	site	NN
1464	1466	is	be	VBZ
1467	1476	sensitive	sensitive	JJ
1477	1479	to	to	TO
1480	1483	PKC	PKC	NNP
1484	1493	depletion	depletion	NN
1493	1494	.	.	.

1495	1503	Moreover	moreover	RB
1503	1504	,	,	,
1505	1520	cotransfections	cotransfection	NNS
1521	1525	with	with	IN
1526	1531	c-fos	c-fos	NN
1532	1535	and	and	CC
1536	1541	c-jun	c-jun	NN
1542	1552	expression	expression	NN
1553	1561	plasmids	plasmid	NNS
1562	1570	markedly	markedly	RB
1571	1578	enhance	enhance	VBP
1579	1588	induction	induction	NN
1589	1591	of	of	IN
1592	1595	the	the	DT
1596	1600	IL-2	il-2	NN
1601	1609	promoter	promoter	NN
1610	1612	in	in	IN
1613	1622	minimally	minimally	RB
1623	1633	stimulated	stimulate	VBN
1634	1635	T	t	NN
1636	1641	cells	cell	NNS
1641	1642	.	.	.

1643	1646	Our	our	PRP$
1647	1654	results	result	NNS
1655	1663	indicate	indicate	VBP
1664	1668	that	that	IN
1669	1672	the	the	DT
1673	1677	AP-1	ap-1	NN
1678	1682	site	site	NN
1683	1685	at	at	IN
1686	1690	-150	-150	CD
1691	1693	bp	bp	NN
1694	1704	represents	represent	VBZ
1705	1706	a	a	DT
1707	1712	major	major	JJ
1712	1713	,	,	,
1714	1716	if	if	IN
1717	1720	not	not	RB
1721	1724	the	the	DT
1725	1729	only	only	JJ
1729	1730	,	,	,
1731	1735	site	site	NN
1736	1738	of	of	IN
1739	1742	PKC	PKC	NNP
1743	1757	responsiveness	responsiveness	NN
1758	1760	in	in	IN
1761	1764	the	the	DT
1765	1769	IL-2	il-2	NN
1770	1778	promoter	promoter	NN
1778	1779	.	.	.